Therapeutic strategies aimed at modulating the deleterious interaction between Serum Amyloid A (SAA) and high-density lipoprotein (HDL) are of increasing clinical interest, particularly in the prevention of cardiovascular and metabolic diseases [64]. The gene discussed is SAA2; the disease is metabolic disease.